Trial Profile

International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Daunorubicin liposomal; Fludarabine; Fludarabine; Methotrexate; Prednisolone
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms Pediatric Relapsed AML 2010/01

Most Recent Events

15 Sep 2022 This trial has been completed in Germany (Global End Date: 8 Jan 2020), according to European Clinical Trials Database record.
12 Feb 2020 This trial has been discontinued in Germany, according to European Clinical Trials Database.
17 Jan 2020 This trial has been discontinued in Czech Republic , according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com